Healthcare provider profile · identity verified

Sujatha Baskar, MD

Allopathic & Osteopathic Physicians|Internal Medicine · TAVARES, FL · NPI 1699764910

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Sujatha Baskar, MD received $58.61 in general payments during 2025 across 2 reported records.

Otsuka America Pharmaceutical, Inc. accounted for 100.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 1 associated product.

A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti.

Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Nuedexta by this doctor in 2024.

Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$58.61

2 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Otsuka America Pharmaceutical, Inc.	Unresolved — no canonical attribution shown	$58.61	100.0%	2	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$58.61	2

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
REXULTI Normalized: rexulti	Drug	Otsuka America Pharmaceutical, Inc.	$58.61	2	2025
Source payment records 2025-02-27 · Otsuka America Pharmaceutical, Inc. · $29.96 · Open Payments source 2025-03-07 · Otsuka America Pharmaceutical, Inc. · $28.65 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
REXULTI rexulti	2025	Rexulti	2024	13 Beneficiary count suppressed	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference	2025	NUEDEXTA open payments reported associated product	CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901	Nuedexta · 2024 Exact normalized brand match · 1 Part D row	21	suppressed by CMS
Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference	2025	REXULTI open payments reported associated product	CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708	Rexulti · 2024 Exact normalized brand match · 1 Part D row	13	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	628	116
Atorvastatin Calcium	Atorvastatin Calcium	536	129
Amlodipine Besylate	Amlodipine Besylate	523	122
Gabapentin	Gabapentin	384	67
Metformin Hcl	Metformin Hcl	343	84
Eliquis	Apixaban	327	48
Rosuvastatin Calcium	Rosuvastatin Calcium	321	85
Metoprolol Succinate	Metoprolol Succinate	294	81
Losartan Potassium	Losartan Potassium	287	74
Lisinopril	Lisinopril	274	64
Metoprolol Tartrate	Metoprolol Tartrate	263	67
Potassium Chloride	Potassium Chloride	259	68
Escitalopram Oxalate	Escitalopram Oxalate	248	63
Clopidogrel	Clopidogrel Bisulfate	220	45
Simvastatin	Simvastatin	198	50
Buspirone Hcl	Buspirone Hcl	194	44
Furosemide	Furosemide	187	57
Alprazolam	Alprazolam	186	47
Trazodone Hcl	Trazodone Hcl	176	45
Pantoprazole Sodium	Pantoprazole Sodium	172	60
Sertraline Hcl	Sertraline Hcl	164	46
Donepezil Hcl	Donepezil Hcl	154	36
Glimepiride	Glimepiride	154	36
Omeprazole	Omeprazole	142	52
Hydrochlorothiazide	Hydrochlorothiazide	140	41
Tramadol Hcl	Tramadol Hcl	137	47
Azithromycin	Azithromycin	126	90
Memantine Hcl	Memantine Hcl	124	21
Tamsulosin Hcl	Tamsulosin Hcl	121	26
Levetiracetam	Levetiracetam	115	13
Prednisone	Prednisone	115	64
Carvedilol	Carvedilol	106	28
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	101	34
Mirtazapine	Mirtazapine	98	25
Xarelto	Rivaroxaban	98	suppressed
Baclofen	Baclofen	91	16
Bupropion Xl	Bupropion Hcl	91	22
Cephalexin	Cephalexin	90	49
Tizanidine Hcl	Tizanidine Hcl	85	21
Spironolactone	Spironolactone	83	20
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	82	13
Duloxetine Hcl	Duloxetine Hcl	77	20
Allopurinol	Allopurinol	74	18
Montelukast Sodium	Montelukast Sodium	74	25
Glipizide	Glipizide	73	15
Pioglitazone Hcl	Pioglitazone Hcl	73	15
Quetiapine Fumarate	Quetiapine Fumarate	73	30
Albuterol Sulfate Hfa	Albuterol Sulfate	72	42
Hydralazine Hcl	Hydralazine Hcl	72	22
Lorazepam	Lorazepam	72	21
Ciprofloxacin Hcl	Ciprofloxacin Hcl	69	43
Divalproex Sodium	Divalproex Sodium	68	11
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	64	41
Fluoxetine Hcl	Fluoxetine Hcl	61	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	61	36
Methylprednisolone	Methylprednisolone	61	43
Clonazepam	Clonazepam	57	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	57	19
Nifedipine Er	Nifedipine	57	12
Ondansetron Hcl	Ondansetron Hcl	57	31
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	53	11
Pregabalin	Pregabalin	53	suppressed
Tradjenta	Linagliptin	53	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	52	11
Methocarbamol	Methocarbamol	51	27
Nystatin	Nystatin	50	26
Isosorbide Mononitrate Er	Isosorbide Mononitrate	49	suppressed
Bumetanide	Bumetanide	48	15
Carbidopa-Levodopa	Carbidopa/Levodopa	47	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	46	suppressed
Atenolol	Atenolol	45	11
Citalopram Hbr	Citalopram Hydrobromide	45	11
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	45	11
Temazepam	Temazepam	44	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	44	suppressed
Lactulose	Lactulose	43	16
Lovastatin	Lovastatin	43	suppressed
Midodrine Hcl	Midodrine Hcl	43	15
Ropinirole Hcl	Ropinirole Hcl	43	suppressed
Fluticasone Propionate	Fluticasone Propionate	42	18
Pravastatin Sodium	Pravastatin Sodium	42	14
Meclizine Hcl	Meclizine Hcl	41	17
Sucralfate	Sucralfate	41	suppressed
Celecoxib	Celecoxib	40	12
Clonidine Hcl	Clonidine Hcl	40	19
Doxepin Hcl	Doxepin Hcl	40	17
Fluconazole	Fluconazole	40	22
Tresiba Flextouch U-100	Insulin Degludec	40	suppressed
Cefuroxime	Cefuroxime Axetil	39	26
Jardiance	Empagliflozin	39	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	38	suppressed
Solifenacin Succinate	Solifenacin Succinate	38	13
Budesonide	Budesonide	37	11
Sotalol	Sotalol Hcl	37	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	35	18
Labetalol Hcl	Labetalol Hcl	35	suppressed
Meloxicam	Meloxicam	35	11
Oxybutynin Chloride	Oxybutynin Chloride	34	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	33	12
Famotidine	Famotidine	33	12
Finasteride	Finasteride	33	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	33	suppressed
Primidone	Primidone	33	suppressed
Ezetimibe	Ezetimibe	32	14
Amiodarone Hcl	Amiodarone Hcl	31	suppressed
Digoxin	Digoxin	31	11
Fludrocortisone Acetate	Fludrocortisone Acetate	31	suppressed
Humalog Kwikpen U-100	Insulin Lispro	30	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	30	suppressed
Mounjaro	Tirzepatide	30	suppressed
Synthroid	Levothyroxine Sodium	30	suppressed
Levalbuterol Hcl	Levalbuterol Hcl	29	suppressed
Levemir Flexpen	Insulin Detemir	28	suppressed
Aripiprazole	Aripiprazole	26	suppressed
Admelog	Insulin Lispro	24	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	24	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	24	suppressed
Alendronate Sodium	Alendronate Sodium	23	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	23	suppressed
Brilinta	Ticagrelor	23	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	23	suppressed
Repaglinide	Repaglinide	23	suppressed
Clobetasol Propionate	Clobetasol Propionate	22	11
Valacyclovir	Valacyclovir Hcl	22	suppressed
Diclofenac Sodium	Diclofenac Sodium	21	suppressed
Januvia	Sitagliptin Phosphate	21	suppressed
Metronidazole	Metronidazole	21	13
Nuedexta	Dextromethorphan Hbr/Quinidine	21	suppressed
Eszopiclone	Eszopiclone	20	suppressed
Ibuprofen	Ibuprofen	20	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	20	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	20	suppressed
Trulicity	Dulaglutide	20	suppressed
Carbidopa-Levodopa-Entacapone	Carbidopa/Levodopa/Entacapone	19	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	19	suppressed
Cholestyramine	Cholestyramine (With Sugar)	19	suppressed
Ertapenem	Ertapenem Sodium	19	suppressed
Ketoconazole	Ketoconazole	19	13
Morphine Sulfate Er	Morphine Sulfate	19	suppressed
Latanoprost	Latanoprost	18	suppressed
Metformin Hcl Er	Metformin Hcl	18	suppressed
Risperidone	Risperidone	18	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	18	suppressed
Fosfomycin Tromethamine	Fosfomycin Tromethamine	17	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	17	suppressed
Ventolin Hfa	Albuterol Sulfate	17	suppressed
Amoxicillin	Amoxicillin	16	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	16	suppressed
Irbesartan	Irbesartan	16	suppressed
Linzess	Linaclotide	16	suppressed
Mupirocin	Mupirocin	16	12
Nitroglycerin	Nitroglycerin	16	11
Novolog Flexpen	Insulin Aspart	16	suppressed
Paroxetine Hcl	Paroxetine Hcl	16	suppressed
Ranolazine Er	Ranolazine	16	suppressed
Rybelsus	Semaglutide	16	suppressed
Benazepril Hcl	Benazepril Hcl	15	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	15	12
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	15	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	14	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	14	suppressed
Sodium Chloride	0.9 % Sodium Chloride	14	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	14	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	13	suppressed
Insulin Aspart Flexpen	Insulin Aspart	13	suppressed
Lamotrigine	Lamotrigine	13	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	13	suppressed
Rexulti	Brexpiprazole	13	suppressed
Valsartan	Valsartan	13	suppressed
Admelog Solostar	Insulin Lispro	12	suppressed
Benztropine Mesylate	Benztropine Mesylate	12	suppressed
Colchicine	Colchicine	12	suppressed
Constulose	Lactulose	12	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	12	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	12	suppressed
Olanzapine	Olanzapine	12	suppressed
Silver Sulfadiazine	Silver Sulfadiazine	12	suppressed
Trihexyphenidyl Hcl	Trihexyphenidyl Hcl	12	suppressed
Warfarin Sodium	Warfarin Sodium	12	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	12	suppressed
Zenpep	Lipase/Protease/Amylase	12	suppressed
Diltiazem 12hr Er	Diltiazem Hcl	11	suppressed
Glycopyrrolate	Glycopyrrolate	11	suppressed
Insulin Lispro	Insulin Lispro	11	suppressed
Permethrin	Permethrin	11	suppressed
Promethazine Hcl	Promethazine Hcl	11	suppressed
Torsemide	Torsemide	11	suppressed
Vraylar	Cariprazine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$58.61 · 2 records	Otsuka America Pharmaceutical, Inc.	REXULTI	2	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Rexulti play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with Otsuka America Pharmaceutical, Inc.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error